Kornimate/medical-research-clean huggingface dataset:
assessment of functional capacity in long-covid

Conditions: Post-COVID-19 Syndrome; Long COVID

Summary: a paucity of prognostic studies in patients with post-covid-19 syndrome (long-covid) shows the need to identify the main effects on functional capacity in the short and medium term. in this regard, the evaluation of lung function, lung structure and functional capacity in long-covid patients is essential to estimate the impact of the disease. this retrospective observational study aims to compare functional capacity, lung function, and lung ultrasound findings in patients who underwent physical therapy to those who did not.

introduction: the pandemic caused by the severe acute respiratory syndrome by coronavirus 2 (sars-cov-2) has been presented as a one of the greatest health challenges on a global scale at the beginning of this millennium. many patients need physical therapy in their recovery process. a paucity of prognostic studies in patients with long-covid shows the need to identify the main repercussions on functional capacity in the short and medium term. in this regard, the evaluation of lung function, lung structure and functional capacity in long-covid patients is essential to estimate the impact of the disease. objective: the present study aims to compare functional capacity, lung function, and lung ultrasound findings between patients diagnosed with long-covid who underwent physical therapy to those who did not. methods: this is a retrospective observational study with quantitative data analysis. the study will be carried out at the pulmonary function laboratory of the policlínica universitária piquet carneiro, from the state university of rio de janeiro. first, a clinical evaluation will be performed. in the survey, it will be asked whether the patient had undergone physical therapy treatment, so they can be allocated in the control or intervention group. after that, they will answer to the post-covid-19 functional status scale (pcfs), a tool to measure functional status over time after covid-19. then, patients will have their lung function evaluated through spirometry and impulse oscillometry (ios). in addition, lung ultrasound (lus) images will be analyzed. and their functional capacity will be assessed using the six-minute walk test (6mwt) coupled to pulmonary ventilation measurement using spiropalm® (spiropalm 6mwt, cosmed, rome, italy). it is expected that understanding the consequences of long-covid on pulmonary ventilation can help to design therapeutic strategies in rehabilitation services.

Eligibility criteria:
inclusion criteria: individuals with an established diagnosis of covid-19 (rt-pcr) who required hospitalization or not, regardless of whether or not they were treated in the icu. exclusion criteria: patients unable to perform the tests. patients with musculoskeletal disorders not associated with covid-19. patients with lung, heart or cerebrovascular diseases not associated with covid-19.

Keywords: functional capacity; six-minute walk test; spirometry; oscillometry; lung ultrasound; ventilometry;
sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis

Conditions: Cystic Fibrosis; Rhinosinusitis

Summary: rhinosinusitis disorders are almost regularly associated to cystic fibrosis (cf). the basic defect in cf is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. it leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection. in cf rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ent) surgery and accelerate disease progression by bacterial acquisition into the airways. the multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ent-related quality of life which is influenced by mucus retention and the resulting inflammation.


Eligibility criteria:
inclusion criteria: * subject has a confirmed diagnosis of cystic fibrosis based on: 2 positive sweat chloride tests and/or genetic characterization * subject is 8 years of age or older * informed consent of the patient or legal representative * women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol (failure rate \<1% e.g. implants, combined oral contraceptives, injectables, some intrauterine devices, sexual abstinence or vasectomised partner) exclusion criteria: * subject has no chronic rhinosinusitis (european position paper on rhinosinusitis and nasal polyps (epos-criteria) * subject has a critical condition defined as: forced expiratory volume at one second \< 30% and / or arterial oxygen saturation \< 93% without o2-substitution; need of o2-substitution * subject had an ent surgery within 6 months prior to study * subject participates in another clinical trial within 30 days prior to study entry

Keywords: cystic fibrosis chronic rhinosinusitis
budesonide application via mucosal atomization device as a treatment for chronic rhinosinusitis when utilized as a topical nasal steroid spray

Conditions: Chronic Rhinosinusitis

Summary: budesonide, a steroid subtype, has been used as an adjunctive treatment for chronic rhinosinusitis as a topical nasal steroid spray. the current standard of care at st. paul's sinus centre is to administer budesonide via the mucosal atomization device (mad). it is believed that the mad is a better device than the standard nasal lavage because its fine mist enhances absorption and improves bioavailability. no studies have been done to determine if enhanced absorption and improved bioavailability of budesonide via mad could potentially affect the hypothalamic-pituitary-adrenal (hpa) axis, resulting in the suppression of our own body's production of natural steroids.


Eligibility criteria:
inclusion criteria: * 19 years of age or older * diagnosed with crs with or without polyps * awaiting for functional endoscopic sinus surgery * give consent on their own exclusion criteria: concurrent or recent use (within the past 30 days) of systemic corticosteroids * history of pituitary disease * morbid obesity (body mass index \[calculated as weight in kilograms divided by height in meters squared\] * concurrent or recent use of medications that accelerate the clearance of cortisol: o such as dilantin, rifampin, amphetamines, or lithium carbonate * concurrent use of medications that interfere with the production of cortisol: o such as ketoconazole, amphotericin b, bupropion, echinacea, fluoroquinolones, itraconazole, licorice * use of oral contraception * use of female or male hormone therapy * known hypersensitivity to cortisol, corticotropin, or cosyntropin
clinical study comparing the efficacy and safety of idp-126 gel in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: this is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of idp-126 gel in comparison idp-126 vehicle gel at weeks 2, 4, 8, and 12.


Eligibility criteria:
inclusion criteria: * male or female at least 9 years of age and older. * written and verbal informed consent must be obtained. subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit). * subject must have an evaluator's global severity score (egss) of 3 (moderate) or 4 (severe) at the baseline visit. * subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100. * subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150. * subjects with 2 or fewer facial nodules. exclusion criteria: * any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema. * any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. * subjects with more than 2 facial nodules. * female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study. * use of estrogens (eg, depogen, depo-testadiol, gynogen, valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study. * treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area. * subjects who have not undergone specified washout period(s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area. * subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications. * subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study.
study of the effect of inhaled anesthetics on diastolic heart function using a doppler-derived efficiency index

Conditions: Diastolic Dysfunction; Coronary Artery Disease; General Anesthesia

Summary: the purpose of this study is to determine the effect of inhaled anesthetic drugs upon diastolic heart function (heart suction and filling performance) in patients who are undergoing coronary bypass surgery.

diastolic heart dysfunction is a significant cause of cardiovascular morbidity and is the cause of symptomatic heart failure in approximately one half of patients who are admitted to hospitals with heart failure symptoms. however, diastolic heart function remains difficult to measure objectively without cardiac catheterization. diastolic heart dysfunction is also common among patients undergoing coronary bypass grafting (cabg) surgery. despite the ubiquitous use of inhaled volatile drugs to maintain anesthesia in these patients, their effects upon diastolic heart function remain unclear.

Eligibility criteria:
inclusion criteria: * non-emergent coronary bypass grafting surgery * left ventricular ejection fraction of 40% or greater exclusion criteria: * myocardial infarction within 4 weeks * greater than mild cardiac valvular pathology * body mass index greater than 35 * cardiac dysrhythmias or pacemaker therapy * left bundle branch block * uncontrolled gastroesophageal reflux disease

Keywords: diastole, physiopathology coronary artery disease volatile anesthetic sevoflurane
expanded access for psv personalized oncolytic viruses

Conditions: Cancer

Summary: a compassionate use, expanded access protocol for patients who have exhausted all standard therapy having progressed on chemotherapy and immunotherapy.

patients will receive intratumoral or subcutaneous injection of an oncolytic virus called psv (short for personalized virus) every other week until the occurrence of immune related recist progression, intolerable toxicity, change to another anti-cancer treatment due to lack of apparent benefit, or personal choice.

Eligibility criteria:
inclusion criteria: * ability to understand and sign a written informed consent form. * measurable or evaluable disease with least one (1) tumor that is accessible to intratumoral injection. * eastern cooperative group (ecog) performance status is 0-3 at screening. * acceptable liver function at screening, as evidenced by: * bilirubin ≤ 3.0 x upper limit of normal (uln) since this patient has * been diagnosed with gilbert's disease * ast (sgot) and alt (sgpt) ≤ 5 x uln. * serum creatinine \< 3 x institution upper limit of normal. * patient has acceptable hematologic status at screening, as evidenced by: * absolute neutrophil count ≥ 1,500 cells/mm3; and * platelet count ≥ 70,000/mm3; and * hemoglobin (hgb) ≥ 8.5 g/dl. * medically acceptable contraception. * willingness to comply with all protocol procedures, evaluations and rescue measures. exclusion criteria: * presence of a serious co-morbid medical condition, or a clinically significant laboratory finding(s) that, in the opinion of the investigator, suggests the presence of an infectious, endocrine, and/or other inadequately treated systemic disorder. * an active bacterial, fungal, or viral infection.

Keywords: cancer
prevention of preterm birth with a pessary in twin gestations

Conditions: Premature Birth; Short Cervix

Summary: preterm birth (ptb) is a major health problem and contributes to more than 50% of the overall perinatal mortality. twins are at increased risk for ptb. the number of twins births has risen substantially due to the increased use of assisted reproductive technology. the rate of twin births in the united states rose from 18.9 to 32.2 per 100 live births between 1980 and 2004. the increased rate of ptb in twins is associated with increased morbidity and mortality rates. almost one in four very low birth-weight infants (below 1500 g) born in the united states are twins, as are one in six infants who die in the first month of life. cervical shortening is a risk factor for ptb. transvaginal ultrasound measurement of cervical length is a reliable screening test for prediction of ptb. there is currently no effective treatment to decrease the incidence of ptb in women with twin gestations, but there is some evidence that the use of a cervical pessary in women with a short cervix has promise. if effective this approach would be particularly appealing because of the wide availability of pessaries, ease of use, and low cost. unfortunately, existing studies are inadequate to confirm effectiveness; a well designed, properly powered, prospective randomized trial is warranted prior to widespread implementation in clinical practice. we propose such a trial to study the effectiveness of the pessary in decreasing the incidence of ptb in an inner city philadelphia population.


Eligibility criteria:
inclusion criteria: * 18-50 years of age * twin pregnancy (limits the participants to female gender) * short cervical length (less than or equal to 30 mm) on second trimester ultrasound at 18-27 6/7 weeks gestation exclusion criteria: * singleton or higher order than twins multiple gestation * monoamniotic twins * twin twin transfusion syndrome * ruptured membranes * lethal fetal structural anomaly * fetal chromosomal abnormality * cerclage in place (or planned placement) * vaginal bleeding * suspicion of chorioamnionitis * ballooning of membranes outside the cervix into the vagina * painful regular uterine contractions * labor * placenta previa

Keywords: premature birth premature delivery short cervix pessary
pearls and pitfalls in usage of plasma-rich platelet graft versus dartos flap in distal penile hypospadias repair

Conditions: Penile Hypospadias

Summary: hypospadias is the most common congenital anomaly of penis. it is the second most common genital birth defect in boys after cryptorchidism the reinforcement of hypospadias repair with an intermediate layer is believed to reduce the incidence of postoperative complications such as uretherocautanous fistula. hypospadias is classified by the location of the abnormal urethral meatus into distal penile (glandular ,subcoronal and distal penile), mid penile and proximal penile hypospadias indeed, uretherocautanous fistula is most common complication after urethroplasty, with introduction of a protective layer between the neourethra and the covering skin strongly reduces fistulas occurrence and the overall complication the aim of the study to evaluate and to compare the use of prp covering layer and dartos fascia flap layer in regard to complication rates in hypospadias repair

hypospadias is the most common congenital anomaly of penis. it is the second most common genital birth defect in boys after cryptorchidism the reinforcement of hypospadias repair with an intermediate layer is believed to reduce the incidence of postoperative complications such as uretherocautanous fistula. hypospadias is classified by the location of the abnormal urethral meatus into distal penile (glandular ,subcoronal and distal penile), mid penile and proximal penile hypospadias indeed, uretherocautanous fistula is most common complication after urethroplasty, with introduction of a protective layer between the neourethra and the covering skin strongly reduces fistulas occurrence and the overall complication the aim of the study to evaluate and to compare the use of prp covering layer and dartos fascia flap layer in regard to complication rates in hypospadias repair

Eligibility criteria:
inclusion criteria: * age \>6 months * distal penile hypospadias * denovo hypospadias exclusion criteria: * recurrent hypospadias -mid and proximal penile hypospadias

Keywords: plasma-rich platelet graft dartos flap
imaging for the evaluation of transthyretin cardiac amyloidosis prevalence of patients over 65 hospitalized in cardiology wards (the impact study)

Conditions: Transthyretin Cardiac Amyloidosis

Summary: heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (ttr-cm), especially in elderly people. nevertheless, research of ttr-cm is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. therefore, the exact prevalence of ttr-cm remains unknown. we aim to determine the prevalence of ttr-cm in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (chu de poitiers) by performing bone scintigraphy and research of al amyloidosis.

not provided

Eligibility criteria:
inclusion criteria: * patient ≥ 60 years, hospitalised in cardiology wards of the centre hospitalier universitaire of poitiers * left ventricle hypertrophy on echocardiography * patient able to comply with study procedures * patient legally free and not subject to any custody, guardianship, tutelage or subordination measures * patient having signed an informed consent after clear and fair information on the study exclusion criteria: * cardiactransplant * complex congenital cardiopathies * know diagnosis of amylosis * contra-indication to bony scintigraphy : hypersensitivity to sodium oxidronate or one of its excipients, or to one of the components of radiopharmaceutic marked product ; * subject not able to comply with study procedures * patients not benefiting from a social security scheme or not benefiting from it through a third party * persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, patients staying in a health or social establishment, adults under legal protection, and patients in emergency situation. * women not menopausal

Keywords: cardiology
an epidemiological surveillance study to evaluate the incidence of dengue in brazil

Conditions: Dengue

Summary: the purpose of this study is to estimate the incidence of dengue infection in children and adults in geographically distinct locations of brazil.

the aim of this study is to generate dengue disease burden data including estimates of incidence rates, prevalence data and the clinical presentation of dengue across different age groups. the study will be conducted in at least three cities: rio de janeiro, salvador, and manaus. this study will also prepare potential sites for future clinical trials, by setting up the logistics and training staff on site to enroll a cohort of subjects perform dengue surveillance and other study procedures. households will be randomly selected from communities where a registry system is implemented. all individuals in the household will be eligible for participating in the study. this study will be sponsored by gsk and co-funded by gsk and fiocruz. as study sponsor, gsk will delegate some activities to fiocruz, according to the provisions in their cooperative research and development agreement (crada).

Eligibility criteria:
inclusion criteria: * written, signed or thumb-printed informed consent (and assent when applicable) must be obtained from the subject or subject's parent(s)/legally acceptable representative(s) (lar(s)). if the subject/subject's parent(s)/lar(s) are illiterate the consent form will be countersigned by a witness. * male or female at least 6 months of age at the time of enrollment. * subject and/or subject's parent(s)/lar(s) who the study staff believes can comply with the requirements of the protocol. * subject who plans, at the time of enrollment, to remain at same residence/study area during their study participation period). exclusion criteria: * child in care. * participation (current or planned) in another epidemiological study or in a clinical trial that would conflict with the current study, based on investigator's judgement. * terminal illness or severe mental incapacity.

Keywords: endemic regions brazil incidence surveillance dengue
antioxidant and anti-inflammatory effects of yogurt enriched with polyphenols

Conditions: Oxidative Stress; Inflammation

Summary: the purpose of this study is to investigate the possible antioxidant and anti-inflammatory effects of yogurt enriched with polyphenols after 2-week consumption by healthy individuals.

eighteen healthy adult volunteers of both sexes consumed yogurt (400g per day) enriched with polyphenols (10mg/100g yogurt) or yogurt (400g per day) not enriched with polyphenols for two weeks in a double-blind, crossover, randomized manner.there was a washout period of at least 10 days. physiological data and blood samples were collected before and after consumption of each yogurt.

Eligibility criteria:
inclusion criteria: * healthy individuals * non-smokers exclusion criteria: * current use of dietary supplements or drugs * metabolic disease * lactose intolerance * pregnant, pregnancy intention or breast feeding

Keywords: antioxidant oxidative stress inflammation polyphenols yogurt
reducing reconsolidation of trauma memories with propranolol

Conditions: Posttraumatic Stress Disorder

Summary: the purpose of this study is to test whether propranolol is capable of reducing subsequent physiological trauma-related conditioned responses, as well as self-reported post-traumatic stress disorder (ptsd) symptoms.


Eligibility criteria:
inclusion criteria: * suffer from chronic ptsd for at least 6 consecutive months; * obtain a score of 33 or more on the impact of events scale-revised: * for participants aged 40 years: accept to undergo an electrocardiogram assessment. the results of the electrocardiogram must be normal; * accept to not commence taking new medications on a regular basis during the study. exclusion criteria: * hypotension; * cardiac rhythm below 55 beats per minute; * medical conditions that contraindicates the administration of propranolol; * previous adverse reaction to, or non-compliance with, beta-blockers; * current use of medication that may involve potentially dangerous interactions with propranolol; * any medication that can have an impact on cardiac rhythm; * women who are breast feeding; * past or present bipolar disorder or psychosis, * present substance abuse or dependence, suicidal ideation; * participating in psychotherapy other than support psychotherapy; * an average score above 20 on the dissociative experience scale.